Navigation Links
Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Date:8/19/2007

n of MS to delay the accumulation of disability."

"We now see real hope for changing the course of disease progression for relapsing MS if people with the disease start an effective treatment like Betaseron right away, rather than wait for further clinical signs of MS to occur," said James Simsarian, M.D., past president of the Consortium of Multiple Sclerosis Centers (CMSC) and director of the MS program at the Neurology Center of Fairfax in Fairfax, Virginia.

Other key findings of the BENEFIT follow-up study include:

-- Sensitivity analyses confirmed the robustness of the main findings.

-- Development of neutralizing antibodies did not have an impact on

disability-related or relapse-related outcomes in the trial.

-- Betaseron was safe and well-tolerated, with the reporting of adverse

events (AEs) similar to those previously reported for the drug.(3)

-- 90 percent of the patients who entered the follow-up study elected to

receive Betaseron treatment, indicating high patient acceptance of

treatment. In the study, methods that may have helped patients stay on

therapy included: the implementation of dose titration at the start of

treatment, the use of an auto-injector to give the injections and co-

medication with an analgesic in the first weeks of treatment.

"Bayer HealthCare revolutionized the treatment of MS when we introduced Betaseron as the first disease-modifying treatment," said Darlene Jody, M.D., Senior Vice President and President of Bayer HealthCare's Specialized Therapeutics Global Business Unit. "The BENEFIT results have the potential to again transform the MS treatment paradigm as they provide convincing evidence that treating patients with Betaseron shortly after the first clinical event suggestive of MS can delay disability progression."

About BENEFIT

BENEFIT is a multi-center trial conducted at 98 sites in 20 countries and included pa
'/>"/>

SOURCE Bayer

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
7. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
(Date:7/27/2015)... ... 2015 , ... The FSH Society , the Massachusetts-based ... muscular dystrophy (FSHD), today announced the introduction of the first-ever care guideline for ... published today. , This new guideline condenses the results of nearly 60 ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... Looking ... healthy smile? Horizon Blue Cross Blue Shield of New Jersey has enhanced its Dental ... to take care of their teeth. , “Horizon is committed to offering our ...
(Date:7/27/2015)... AZ (PRWEB) , ... July 27, 2015 , ... The ... who are aging out of the foster care system to get into and complete ... Charitable Trust, was introduced at an event today with partners from across the ...
(Date:7/27/2015)... ... July 27, 2015 , ... A Harris County jury awarded a group ... Canadian stock promoter Robert Kubbernus based on findings of fraud and violations of the ... by the court in Cause No. 2010-09675; Jo Ann Schermerhorn, et al v. CenturyLink, ...
(Date:7/27/2015)... ... July 27, 2015 , ... With a new charity program ... to support its mission of reducing the number of deaths and injuries occurring from ... and their families. PursuitSAFETY works with the police to find better and safer ...
Breaking Medicine News(10 mins):Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3
... model that looks at different strategies for curbing ... isolation may be effective approaches when patients are ... superbugs, such as methicillin-resistant Staphylococcus aureas (MRSA), and ... infections, this type of modeling, if used to ...
... problem that needs to be addressed next is the epidemic ... together to discuss the latest in pain research and treatment ... Pain Medicine (AAPM), February 12-16 at the Gaylord Palms in ... help of their physicians, have been asked to stop smoking ...
... otherwise healthy people have similar survival rates to younger ... older patients can undergo lung transplantation and have good ... patients from having the procedure, a new study says. ... Medical Center reviewed the records of 48 UCLA patients ...
... Proposed Changes in ... Lifesaving Effort, WASHINGTON, Feb. 16 As President Bush ... funded by the,President,s Emergency Plan for AIDS Relief (PEPFAR), the ... request, AIDS Healthcare,Foundation (AHF) ( http://www.aidshealth.org ) today cautioned the ...
... release is also available in French . ... flushing toxic chemicals into the ecosystem through municipal sewer ... comes from an unlikely source: estrogen. , After an ... amounts of estrogen present in municipal wastewater discharges can ...
... Crowder &,DeGaris, P.C. (http://www.cwcd.com ), has filed ... the United States, who allegedly suffered,permanent kidney damage ... to prevent excessive bleeding during coronary,artery bypass graft ... to CBS News, 60 Minutes will report Sunday ...
Cached Medicine News:Health News:Mathematical modeling offers new approaches to fight dual-resistant hospital infections 2Health News:Physicians focus on stopping pain epidemic 2Health News:Physicians focus on stopping pain epidemic 3Health News:Physicians focus on stopping pain epidemic 4Health News:Physicians focus on stopping pain epidemic 5Health News:Physicians focus on stopping pain epidemic 6Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:Bush AIDS Legacy at Risk, Says AHF 2Health News:Fish devastated by sex-changing chemicals in municipal wastewater 2Health News:Fish devastated by sex-changing chemicals in municipal wastewater 3Health News:60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG 2
Bone Curette, 160 mm...
Bone Currettes...
London Endocervical Curette is a stainless-steel curette for obtaining endocervical samples with minimal effort....
...
Medicine Products: